To the Editor We commend Munshi and colleagues1 for their excellent article demonstrating the prognostic value of minimal residual disease (MRD) in multiple myeloma (MM). We agree that these results support MRD as a clinically useful tool for patient management and treatment development. However, we disagree with the authors’ conclusion that these results support the use of MRD as a surrogate end point for long-term clinical outcomes in randomized clinical trials (RCTs).
Little RF, McShane LM, Freidlin B. Myeloma Minimal Residual Disease and Surrogacy. JAMA Oncol. Published online May 11, 2017. doi:10.1001/jamaoncol.2016.5660